AMICUS THERAPEUTICS, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-04-27: Form 8-K; Period of report 2026-04-27; Description 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 1.02.
- 2026-04-23: Form 8-K; Period of report 2026-04-23; Description 8.01 Other Events; Details 8.01.
- 2026-03-03: Form 8-K; Period of report 2026-03-03; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
- 2026-02-20: Form 8-K; Period of report 2026-02-20; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2026-04-27 | 8-K | 2026-04-27 | 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 1.02 On April 27, 2026, in connection with the Merger, the Company repaid in full all outstanding indebtedness and all other amounts due and payable and terminated all commitments under that certain Loan Agreement, dated October 2, 2023, (as amended, restated, amended and restated, supplemented and otherwise modified from time to time prior to the Closing Date, the “Amicus Credit Agreement”), by and among the Company, each of its subsidiaries party thereto, as guarantors, Blackstone Alternative Credit Advisors LP, Blackstone Life Sciences Advisors L.L.C., certain lenders from time to time party thereto and Wilmington Trust, National Association, as agent for the lenders. 2.01 The disclosures under the Introductory Note, Item 3.01, Item 3.03, Item 5.01, Item 5.02 and Item 5.03 are incorporated herein by reference. 3.01 The disclosures under the Introductory Note are incorporated herein by reference. 3.03 The disclosures under the Introductory Note, Item 3.01, Item 5.01 and Item 5.03 are incorporated herein by reference. 5.01 The disclosures under the Introductory Note, Item 3.01, Item 3.03, Item 5.02 and Item 5.03 are incorporated herein by reference. 5.02 The disclosures under the Introductory Note are incorporated herein by reference. 5.03 The disclosures under the Introductory Note are incorporated herein by reference. | ef20071351_8k.htm |
| 2026-04-23 | 8-K | 2026-04-23 | 8.01 Other Events | 8.01 As previously disclosed, on December 19, 2025, Amicus Therapeutics, Inc. ("Amicus") entered into an Agreement and Plan of Merger (the "Merger Agreement") with BioMarin Pharmaceutical Inc. ("BioMarin") and Lynx Merger Sub 1, Inc., a wholly owned subsidiary of BioMarin ("Merger Sub"), providing for the merger of Merger Sub with and into Amicus (the "Merger"), with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin. | ef20070556_8k.htm |
| 2026-03-03 | 8-K | 2026-03-03 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 At a special meeting of stockholders of Amicus Therapeutics, Inc., a Delaware corporation (the “Company” or “Amicus”) held virtually via live webcast on March 3, 2026 (the “Special Meeting”), the Company’s stockholders voted to approve the Company’s pending acquisition by BioMarin Pharmaceutical Inc., a Delaware corporation (“Parent”). | ny20062454x6_8k.htm |
| 2026-02-20 | 8-K | 2026-02-20 | 2.02 Results of Operations and Financial Condition | 2.02 On February 20, 2026, Amicus Therapeutics, Inc. issued a press release announcing its financial results for the fiscal year ended December 31, 2025. | tm266897d1_8k.htm |
| 2026-01-26 | 8-K | 2026-01-26 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 In connection with the previously announced proposed acquisition of Amicus Therapeutics, Inc. (“Amicus”) by BioMarin Pharmaceutical Inc. (“Parent”), Amicus provided the following preliminary unaudited financial information to Parent, which included such information in its preliminary offering memorandum, dated January 26, 2026, relating to Parent’s proposed private placement of senior notes to fund the acquisition of Amicus: As of December 31, 2025, Amicus estimates that it had approximately $294 million in cash, cash equivalents, and marketable securities. 7.01 The information reported under Item 2.02 is hereby incorporated by reference herein. | ef20063881_8k.htm |